Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Total Current Liabilities (2021 - 2025)

Kiniksa Pharmaceuticals International's Total Current Liabilities history spans 5 years, with the latest figure at $139.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 38.33% year-over-year to $139.2 million; the TTM value through Dec 2025 reached $139.2 million, up 38.33%, while the annual FY2025 figure was $139.2 million, 38.33% up from the prior year.
  • Total Current Liabilities reached $139.2 million in Q4 2025 per KNSA's latest filing, up from $123.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $139.2 million in Q4 2025 to a low of $34.4 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $68.8 million, with a median of $55.0 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: fell 27.34% in 2023, then soared 79.46% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $44.8 million in 2021, then grew by 5.0% to $47.1 million in 2022, then surged by 35.27% to $63.7 million in 2023, then skyrocketed by 58.05% to $100.6 million in 2024, then skyrocketed by 38.33% to $139.2 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Total Current Liabilities are $139.2 million (Q4 2025), $123.6 million (Q3 2025), and $117.8 million (Q2 2025).